Friday, March 31, 2023
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Associate Professor of Medicine
Oncology Division
Washington University School of Medicine
St. Louis, Missouri
Assistant Professor
School of Nursing
Clinical Nurse
North Carolina Cancer Hospital
UNC Lineberger Comprehensive Cancer Center
The University of North Carolina at Chapel Hill
Assistant Professor
Midwestern University Chicago College of Pharmacy
Clinical Pharmacy Specialist
Rush University Medical Center
Chicago, Illinois
This activity is intended for hematologists/oncologists, nurses/nurse practitioners, and pharmacists.
The goal of this activity is to increase knowledge and improve competence related to team-based management of patients with newly diagnosed high-risk acute myeloid leukemia (AML).
Upon completion of this activity, participants will:
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Associate Professor of Medicine
Oncology Division
Washington University School of Medicine
St. Louis, Missouri
Assistant Professor
School of Nursing
Clinical Nurse
North Carolina Cancer Hospital
UNC Lineberger Comprehensive Cancer Center
The University of North Carolina at Chapel Hill
Assistant Professor
Midwestern University Chicago College of Pharmacy
Clinical Pharmacy Specialist
Rush University Medical Center
Chicago, Illinois
Medscape, LLC designates this enduring material for a maximum of 0.50
AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medscape, LLC staff have disclosed that they have no relevant financial relationships.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.
Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.50 contact hours are in the area of pharmacology.
Medscape, LLC designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number JA0007105-0000-19-461-H01-P).
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive
AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC / CE Released: 9/25/2019
Valid for credit through: 9/25/2020
processing....
AE = adverse event
AML = acute myeloid leukemia
ANC = absolute neutrophil count
AR = allelic ratio
AZA = azacitidine
BM = bone marrow
CBC = complete blood count
CBF = core binding factor
CEBPA = CCAAT/enhancer-binding protein alpha
chemo = chemotherapy
DEC = decitabine
CI = confidence interval
CPX-351 = liposomal cytarabine-daunorubicin
CR = complete remission
CR1 = first complete remission
CRi = complete response with incomplete neutrophil or platelet recovery
DFS = disease-free survival
DLBCL = diffuse large B-cell lymphoma
DNMT3A = DNA methyltransferase 3 alpha
ECOG = Eastern Cooperative Oncology Group
EFS = event-free survival
FDA = US Food and Drug Administration
FLT3 = fms-like tyrosine kinase 3
Hgb = hemoglobin
HiDAC = high-dose cytarabine
HLA = human leukocyte antigen
HMA = hypomethylating agent
HR = hazard ratio
HSCT = hematopoietic stem cell transplant
IC = intensive chemotherapy
IDH = isocitrate dehydrogenase
IV = intravenous
ITD = internal tandem duplication
LDAC = low-dose cytarabine
LDH = lactate dehydrogenase
MDS = myelodysplastic syndrome
MLL = mixed lineage leukemia
mOS = median overall survival
MPN = myeloproliferative neoplasm
ND = newly diagnosed
NPM1 = nucleophosmin
NR = not reached
OS = overall survival
OT = occupational therapy
PS = performance status
PT = physical therapy
R = right
R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
R/R = relapsed/refractory
SCT = stem cell transplant
SOS = sinusoidal obstruction syndrome
tAML = therapy-related AML
TLS = tumor lysis syndrome
TP53 = tumor protein p53
WBC = white blood cell
WT = wildtype
| « Return to: Expert Recommendations for Treating Newly Diagnosed High-Risk AML |
